Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.

Drugs - 1 Aug 2015

Califano R, Tariq N, Compton S, Fitzgerald D A, Harwood C A, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, Thomas A, Thatcher N, Nicolson M

Abstract excerpt

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying progression and improvement of quality of life over palliative platinum-based chemotherapy. The most common adverse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Consensus
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Diseases

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Quality of Life

Share to Skin Diseases

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 26187773
DOI: 10.1007/s40265-015-0434-6
PMCID: PMC4532717

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.PMID 26187773Read ↗

A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.Semantic proximity Read ↗

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Semantic proximity Read ↗

[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].Semantic proximity Read ↗

Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.Semantic proximity Read ↗

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Safety of gefitinib in non-small cell lung cancer treatment.Semantic proximity Read ↗

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.Semantic proximity Read ↗

Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.Semantic proximity Read ↗

Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus TrametinibSemantic proximity Read ↗

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.